07:13 AM EDT, 03/23/2026 (MT Newswires) -- Apogee Therapeutics ( APGE ) said Monday that 52-week maintenance data from Part A of its phase two trial of zumilokibart in patients with moderate-to-severe atopic dermatitis demonstrated durable maintenance response and "deepening" response for lesional and itch endpoints.

The company said durable maintenance response was observed for both dosing periods of every three months and every six months, along with the deepening response in lesional and itch endpoints. Zumilokibart was also well tolerated in both dosing regimens, Apogee added.

Apogee said it expects to start phase three trials later this year, targeting a potential commercial launch in 2029.

Shares of Apogee Therapeutics ( APGE ) were up more than 15% premarket Monday.